Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

N. Beije, J. Kraan, W. Taal, B. van der Holt, H.M. Oosterkamp, A.M. Walenkamp, L. Beerepoot, M. Hanse, M.E. van Linde, A. Otten, R.M. Vernhout, F.Y.F. de Vos, J.W. Gratama, S. Sleijfer, M.J. van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)226-231
JournalBritish Journal of Cancer
Volume113
Issue number2
DOIs
Publication statusPublished - 2015

Cite this